As an anti-tumoral immune cell, the analysis through the expression of specific cell surface markers, such as TIM3, needs more in-depth prospective studies to assess the its use for AML patients, as well as optimized therapies currently administrated for patients with solid tumor. The gene discussed is HAVCR2; the disease is acute myeloid leukemia.